Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 8.98 0.03 (0.34%) Market Cap: 1.29 Bil Enterprise Value: 1.02 Bil PE Ratio: 0 PB Ratio: 3.31 GF Score: 81/100

Q1 2019 Aurinia Pharmaceuticals Inc Earnings Call Transcript

May 14, 2019 / 08:30PM GMT
Release Date Price: $6.07 (+0.33%)
Operator

Greetings and welcome to the Aurinia Pharmaceuticals First Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dr. Glenn Schulman. Please go ahead, sir.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - Consultant and IR Officer

Thanks, Kevin, and good afternoon, everyone. Welcome to Aurinia's First Quarter 2019 Financial Results Conference Call. Joining me on the call today from the Aurinia team are: Dr. Richard Glickman, Emeritus Chairman, CEO and now adviser to the company; Mr. Peter Greenleaf, Chief Executive Officer; Dennis Bourgeault, Chief Financial Officer; Dr. Neil Solomons, Chief Medical Officer; and Mr. Michael Martin, Chief Operating Officer for Aurinia.

This afternoon, we issued our press release detailing the first quarter 2019 financial results. The press release and the associated financial statement package is available on our website at www.auriniapharma.com and a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot